Although we couldn’t make it to #ASHG2025, our partner Illumina presented a fantastic study on accurate full-length V(D)J clonotype detection using high-quality long reads on the MiSeq™ i100. We’re especially proud that MiXCR was used to enable precise immune repertoire profiling.

A major leap forward in treatment for Addison’s Disease! In a new publication from bioRxiv, researchers pinpointed IFN-γ–producing self-reactive CD4+ T cells as the main drivers of autoimmune adrenalitis in a mouse model. We're proud that MiXCR enabled analysis of TCR clonotypes from scRNAseq.

Gene expression analysis with bulk RNA-seq data traditionally involves many steps (preprocessing, differential expression, pathway enrichment) + bioinformatics expertise Platforma changes that. Watch how we perform gene expression analysis in just a few clicks. www.youtube.com/watch?v=K7aq...

New Case Study featuring MiXCR + Qiagen: University of Antwerp pioneers “celluloepidemiology", revealing infections missed by antibodies and unique signatures linked to long COVID. Find out how they scaled TCR profiling for population-level insights and cut prep time by 25%. bit.ly/498lvsu

You might know us as the creators of MiXCR, and now we've launched Platforma for more powerful downstream functionalities without the coding bottleneck. #NGS #singlecell #VDJ #bioinformatics

Congratulations to Nobel Laureate Shimon Sakaguchi for his groundbreaking work on regulatory T cells! 🧬 We're proud to see our technology, MiXCR, supporting his lab’s research. In a recent study, MiXCR helped the team decode TCR repertoires. Proud to support science that changes the world. 🌍

Biologists design brilliant experiments...then lose momentum waiting for results. That’s why we built Platforma, to put the power of analysis directly into biologists’ hands. 🎥 Watch the demo to see how Platforma takes you from raw data to validated T-cell insights, without any coding.

October is Breast Cancer Awareness Month, a timely moment to spotlight new advances in how we understand and treat this disease. 🎗️ A recently study explores dynamic systemic immune responses in early-stage HR+ patients receiving chemotherapy + immunotherapy. Read more here: shorturl.at/jOQkO

Fast insights from single-cell data without coding With Platforma, you can: 🔹 Explore UMAPs & Leiden clusters 🔹 Integrate transcriptomics + VDJ metrics 🔹 Visualize clonotypes & sequence similarities 🔹 Overlay gene expression across clusters 🎥 youtu.be/FrsS3YDauhg #singlecell #VDJ #NGS

A new study from @ox.ac.uk shows why HR+ patients with lymph node metastasis fare worse: - Weakened Defense: Tumor-reactive CD8 T cells are scarce, impairing cancer surveillance. - Early-Stage Window: Early HR+ patients have a robust, diverse circulating CD8 TCR More details: shorturl.at/0HP2l

We’re thrilled to team up with @yefis-immunology.bsky.social for our next webinar! 📅 October 7th, 16:00 CET Platforma was built to make cutting-edge bioinformatics accessible to every scientist, so anyone can turn raw NGS into meaningful insights without coding. 🔗 Register here: shorturl.at/AQtCD

Last week we hosted a webinar with Kiel University and shared valuable insights on T-cell responses against EBV (Epstein–Barr Virus) and its implications for advancing research and therapeutic development. Weren't able to attend? 🎥 Watch the recording here: www.youtube.com/watch?v=l2Q8...

💡Why repertoire clonality matters and how to analyze it Done right, repertoire analysis transforms sequencing data into actionable insights for immune monitoring and therapy evaluation. bit.ly/4gBZlRp

Location, location, location. Developing a multimodal framework, new research from @bcmhouston.bsky.social reveals that a T cell's location within a tumor is a major factor influencing its function. We're proud that MiXCR enabled comprehensive TCR repertoire profiling in this study.

Prioritizing antibody candidates shouldn’t require coding bioinformatics expertise. With Platforma, biologists in academia or pharma can analyze NGS data independently, explore motifs, predict liabilities, and select the best antibody leads with confidence. #antibody #bcr #bioinformatics

🚨 Last chance to register! We’re going live tomorrow to explore the link between Epstein-Barr Virus (EBV) and Primary Sclerosing Cholangitis (PSC) with insights from large-scale immune profiling. 📅 Wednesday, Sep 17 @ 3:00 PM GMT+2 💻 Live demo included Register here: shorturl.at/E4tpj

🌍 Exciting news! We’ve launched the Platforma Ambassador Program—a chance for researchers to host workshops, lead user groups, and join a global network of innovators in bioinformatics. Gain training, travel grants & career growth. Apply by Sept 21 👉 shorturl.at/KN2Ju

For the first time, CLL's immune dysfunction has been mapped at single-cell resolution. A new @nature.com study reveals galectin-9 is a key driver of T-cell exhaustion and linked to worse outcomes. Using MiXCR, scientists reconstructed TCR repertoires to uncover these dynamics #CLL #TCell #TCR

🦠 Could Epstein–Barr virus (EBV) be a hidden driver of chronic liver disease? A new Nature Medicine study shows EBV may play a major role in primary sclerosing cholangitis (PSC). 🧵 Key findings ⬇️

9 patients. 40 months. 0 recurrences. 💉 A new Nature study shows the power of personalized cancer vaccines. With the help of MiXCR, researchers designed vaccines targeting each patient’s tumor profile, leading to strong T cell responses. A big step for immunotherapy in hard-to-treat cancers.

✨ Feeling the energy at IUIS! The excitement is contagious, and we loved sharing a live demo of Platforma with so many of you today. 🚀 If you missed it, no worries — we’ll be back tomorrow at 11 AM at the Cellecta booth. Come by to see the future of immune profiling.

How long does vaccine protection actually last? A @nature.com study on Ebola vaccines found B cell immunity still going strong 4+ years later. MiXCR enabled early gene expression predicted antibody levels and uncovered targeted clonal expansion Try MiXCR on Platforma for free (link in bio)

💡 Unlock immune insights in minutes, no coding required! Join us at @iuis-online.bsky.social in Vienna for a live demo of Platforma that will change the way you work with NGS data. 📅 Aug 19 @ 15:00–15:30 📅 Aug 20 @ 11:00–11:30 📍 Booth #75 Limited spots, so don't wait to sign up: tally.so/r/w4b8er

A new study in @nature.com reveals how TCRs recognize neoantigens. They found that a specific mutation creates a stable binding site that helps T cells identify tumor cells. We're proud that MiXCR enabled the structural characterization of tumor-reactive TCRs. Read more here: shorturl.at/Pppzn

We're excited to attend the @iuis-online.bsky.social conference in Vienna! Whether you're working on TCR/BCR discovery, single-cell data, or vaccine development, Platforma can take you from raw NGS data to high-potential candidates, no coding required. 📅 Meet with us: shorturl.at/ufaTF

Great news - MiXCR just got even easier to use. You're using the exact same trusted MiXCR engine, now boosted with Platforma's GUI and powerful downstream analysis tools. And - it’s still completely free for academia. 📽️ Watch this short video and accelerate your research today: shorturl.at/dZdEp

We're hiring! Are you passionate about science and communication? Do you love helping others understand complex topics and solving problems? Join our team in Bilbao as a Documentation Writer and Bioinformatics Support Agent! lnkd.in/eqxu3bts

🫀 New in Nature Cardiovascular Research: APOB-reactive CD4⁺ T cells shift from regulatory to pro-inflammatory in severe CAD. 🔬 Using AIM assays + transcriptomics, researchers uncovered key immune drivers of atherosclerosis—powered by MiXCR for TCR tracking. Full article: shorturl.at/N3dDk

🔬 New insights: A Researcher’s Guide to TCR/BCR Repertoire Analysis Navigating the ecosystem of analysis tools can be overwhelming. We break it down - from alignment to downstream analysis. Perfect for those working in bulk or single-cell immune repertoire profiling. Read here: shorturl.at/8YMWA

We gave our website a glow-up ✨ Redesigned with biologists in mind: clearer structure, new resource pages, and a smoother experience. Check it out here: shorturl.at/IPnal

Feeling the love from the bioinformatics community ♥️ this is why we do what we do

🔬 Can standard RNA-Seq unlock hidden immune insights? In a new study of 766 myeloma patients, researchers reconstruct full-length antibody light-chain sequences, without targeted immune sequencing. Read more here: shorturl.at/4nTdZ #Immunology #CancerResearch #Antibody

🦠 How does memory T cell function differ between hospitalized and non-hospitalized individuals following COVID-19? New insights discovered that non-hospitalized individuals achieve broader, more diverse TCR responses—likely leading to more durable immunity. 📄 Read more here: shorturl.at/8BehZ

We're hiring our first sales rep to join us on our next phase of growth! If you're curious about biotech, fluent in English, and love turning complex science and engineering into clear value for users — let’s talk. Apply here: www.linkedin.com/jobs/view/42...

Unlock hidden patterns in your single-cell immune repertoire data in minutes, not weeks. This new guide from @10xgenomics.bsky.social walks you through how to use MiXCR for in-depth analysis of TCR/BCR sequences. Check it out here: shorturl.at/JntYx #SingleCell #Immunology #TCR #BCR

🧬 Can ovarian cancer be detected through a simple blood test? A new study analyzing the TCR repertoire with machine learning says yes, and they also utilized MiXCR to extract key immune signatures to enable non-invasive early detection. Read more here: shorturl.at/Ml1aQ #Immunology

What if we could predict how your immune system will respond, before you even receive treatment? Thanks to AI, we can. From detecting super-responders to identifying novel antibodies, artificial intelligence is fundamentally transforming immunology research. Read more here: shorturl.at/HwUQS

🔬 Why do some cancer patients respond to cell therapy while others don't? We’re excited to answer this question in our next webinar: Decoding Adoptive Cell Therapy Response with ImmuneWatch. Register here: shorturl.at/063UV #CancerImmunology #AdoptiveCellTherapy #SingleCell #CellTherapy

Millions of clones to a publication-ready plot in seconds. Sound impossible? It's not. In our new video, watch as we instantly visualize the results of a longitudinal study to pinpoint the peak of immunization. Accelerate your discoveries today with Platforma: shorturl.at/dZdEp #Bioinformatics

Can TCR clonality predict outcomes in NSCLC patients on immunotherapy? A new bioRxiv study links T-cell expansion to mutations, immune phenotypes & survival. MiXCR helps uncover these insights—now free for academia on Platforma: shorturl.at/dZdEp Full article: tinyurl.com/5cwfzzz5

Did you know our technology is used by researchers at 47 of the top 50 universities globally? Since we published in @nature.com, thousands of scientists trust MiXCR for immune repertoire analysis, and for good reason. Get started with MiXCR today, as part of Platforma: shorturl.at/dZdEp

How do our immune systems respond to vaccines at the molecular level? In this short clip from our recent webinar, we highlight how multiomics is transforming our understanding of immune function. 👉 Watch the full webinar and explore the insights from the study: tally.so/r/meG6aQ

We're thrilled you're enjoying Platforma — it means a lot to us. If anyone else is looking for an intuitive, no-code bioinformatic tool, definitely check us out: shorturl.at/dZdEp

🧬 Scientific Spotlight: A recent study published in @springernature.com showcases how RNA‑seq should be a diagnostic tool, as it offers insights on a patient’s immune status. We're proud that MiXCR helped classify immune responses across different COVID variants. Read more here: shorturl.at/oqjMo

Last chance to register! Registration link: lu.ma/y42wzbe9

🧬 What really happens to your immune system after a vaccine? Find out in the next session of our Platforma webinar series, this time in collaboration with Cellecta! Register here: lu.ma/y42wzbe9 #ImmuneProfiling #Vaccines #Multiomics

🔬 Are you spending too much time analyzing your antibody/TCR data? You might be delaying your next breakthrough. With Platforma, you can turn entire NGS clonotype datasets into actionable insights in minutes — no coding required. 👉 Watch a 1 minute demo video: shorturl.at/o3hiM #immunology #TCR

Can we go beyond PD-1 inhibitors in cancer immunotherapy? A new Cell Reports study says yes—and Flt3L might be the key. It diversifies TCR repertoire, something PD-1 inhibitors alone can't do - a promising new approach to overcome immunotherapy resistance. Read more: www.cell.com/cell-reports...

🔎 MiLabs Research Spotlight! Neogene, an AstraZeneca company, has developed a new TCR discovery platform. MiXCR played an important role in identifying TCR chains and clonotypes. 👉 Download MiXCR, as part of Platforma (free for academia): Link in bio Read more: www.nature.com/articles/s41...

🔎 MiLabs Research Spotlight New Nature Immunology study shows lung-specific SARS-CoV-2 T cells help clear the virus & form resident memory for lasting protection! MiXCR powered immune profiling in this breakthrough. 📖 Read more: t.co/umQZUqUH69 #COVID19 #MiXCR #MiLabsResearchSpotlight